VEGFR
Vascular endothelial growth factor receptor
VEGFRs consist of three subtypes, the fms-like tyrosine kinase Flt-1 (VEGFR1/Flt-1), the kinase domain region, also referred to as fetal liver kinase (VEGFR2/KDR/Flk-1), and Flt-4 (VEGFR3). Each receptor has seven immunoglobulinlike domains in the extracellular domain, a single transmembrane region, and a consensus tyrosine kinase sequence interrupted by a kinase insert domain. VEGFR1 and 2 are expressed on vascular endothelial cells, whereas VEGFR3 is expressed on lymphatic endothelial. The VEGF family members VEGF-A, -B, -C, -D, -E, and PlGF, and the human immunodeficiency (HIV) Tat protein bind in specific patterns to three related receptor protein tyrosine kinases, VEGFR1, 2, and 3, and induce the formation of homo- and heteromeric receptor complexes. Binding of VEGF to VEGFR causes dimerization and autophosphorylation of the receptor. Intracellular proteins such as VEGFR-associated protein (VRAP), PLC, and Sck that associate with specific tyrosine residues of VEGFR are phosphorylated upon receptor activation. Several signal transduction pathways are activated by the binding of VEGF to its receptor, leading to increased proliferation, survival, permeability, and migration of cells.
VEGFR Isoform Specific Products
All Product Categories
-
VEGFR Inhibitors
(721)
View all products
-
VEGFR Agonists
(7)
View all products
-
VEGFR Antagonists
(6)
View all products
-
VEGFR Activators
(16)
View all products
-
VEGFR Modulators
(6)
View all products
-
VEGFR Chemical
(1)
View all products
-
VEGFR Inducer
(1)
View all products
-
VEGFR Degraders
(4)
View all products
-
VEGFR Ligands
(6)
View all products
-
VEGFR Proteins
(36)
View all products
-
VEGFR-1 Proteins
(10)
View all products
-
VEGFR-3 Proteins
(7)
View all products
-
VEGFR Related Products (815)
Related Products (815)
-
Recombinant Proteins (36)
-
Antibodies (9)
-
VEGFR Isoform Comparison
-
VEGFR-2-IN-70
0 ImagesCat. No.: HY-175019VEGFR-2-IN-70 is a potent VEGFR-2 inhibitor with an IC50 of 18.04 nM. VEGFR-2-IN-70 exhibits cytotoxicity against A549 and MCF-7 cancer cells with IC50 values of 0.43 μM and 3.8 μM, respectively. VEGFR-2-IN-70 induces G1 cell cycle arrest and apoptosis in lung cancer cells. VEGFR-2-IN-70 is useful in cancer research.
-
VEGFR-2-IN-19
0 ImagesCat. No.: HY-146367CAS No.: 2456315-41-4VEGFR-2-IN-19 (Compound 15b) is a potent VEGFR2 inhibitor. VEGFR-2-IN-19 induces cell apoptosis and increases intracellular reactive oxygen species level. VEGFR-2-IN-19 can be used as an anticancer agent.
-
EG01449 Free acid
0 ImagesCat. No.: HY-179350EG01449 Free acid is a quinoline-based antagonist of Neuropilin-1 (NRP1) with an Kd of 0.6 µM. EG01449 Free acid competitively inhibits the binding of VEGFA to NRP1 with an IC50 of 362 nM. EG01449 Free acid prevents VEGFA-induced pain by inhibiting NRP1-dependent signaling and reducing sodium currents in sensory neurons. EG01449 Free acid can be used for the research of nociceptive pain.
-
GPVGPS
0 ImagesCat. No.: HY-P11890CAS No.: 1154403-54-9GPVGPS is a low-molecular-weight fish collagen peptide. GPVGPS upregulates the expression of vascular endothelial growth factor (VEGF), PCNA, hepatocyte growth factor, epidermal growth factor (EGF) , and insulin-like growth factor 1 (IGF-1), and downregulates the expression of negative regulatory proteins associated with hair health. GPVGPS inhibits MMP-1, MMP-2, and MMP-9, increases skin water content, reduces wrinkles, and improves oxidative stress status and pro-inflammatory cytokine levels. GPVGPS can be used in studies related to hair loss and UVB-induced skin photoaging.
-
VEGFR-2-IN-60
0 ImagesCat. No.: HY-170549CAS No.: 3116929-46-2VEGFR-2-IN-60 (compound 5c) is a potent VEGFR-2 inhibitor with an IC50 of 1.07 nM. VEGFR-2-IN-60 exhibits cytotoxic activity against HCC1806, Hela, and A549 cell lines.
-
7-Hydroxyneolamellarin A
0 ImagesCat. No.: HY-N10330CAS No.: 959662-26-17-Hydroxyneolamellarin A is a natural product that could be derived from sponge Dendrilla nigra. 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1α (HIF-1α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1α (HIF-1α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer.
-
TU-100
0 ImagesCat. No.: HY-165386CAS No.: 1310907-71-1TU-100 is a Japanese herbal medicine. TU-100 exhibits anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. TU-100 can antagonize the M2 polarization phenotype of macrophages in the tumor microenvironment by suppressing the TLR4/NF-κB/STAT3 axis. TU-100 can inhibit the high expression of MMP-2, COX-2, and VEGF in TAMs.
-
hVEGF-IN-2
0 ImagesCat. No.: HY-148316CAS No.: 186610-88-8hVEGF-IN-2 (compound 19) is a selective VEGF (Flk-1) receptor tyrosine kinases (RTK) inhibitor with an IC50 value of 2.5 μM. hVEGF-IN-2 inhibits PDGF RTK activity with an IC50 value of 33.1 μM. hVEGF-IN-2 can be used for the development of RTK-specific agents.
-
VEGFR-2-IN-27
0 ImagesCat. No.: HY-146236CAS No.: 2439096-14-5VEGFR-2-IN-27 (compound 7a) is a highly potent VEGFR-2 inhibitor with an IC50 value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer.
-
A-176120
0 ImagesCat. No.: HY-117807CAS No.: 185049-54-1A-176120 is a selective inhibitor of farnesyl transferase (IC50=1.2 nM) based on a farnesyl pyrophosphate (FPP) analog, with superior selectivity against GGTaseI (IC50=423 nM), GGTaseII (IC50=3000 nM), and SSase (IC50>10 μM). A-176120 inhibits ras processing in H-ras transformed NIH3T3 cells and HCT116 K-ras mutant cells (ED50=1.6 and 0.5 μM, respectively). A-176120 has antiangiogenic and antitumor activities in vivo and reduces capillary structure formation and VEGF secretion.
-
THR-317
0 ImagesCat. No.: HY-P991429THR-317 is a human monoclonal antibody (mAb) targeting PLGF. THR-317 can be used in Diabetic retinopathy research.
-
BPTQ
0 ImagesCat. No.: HY-124122CAS No.: 1802665-43-5BPTQ is a potent inhibitor against VEGFR1 and CHK2 with IC50 values of 0.54 and 1.70 µmol/L, respectively. BPTQ is also an intercalator of DNA with anticancer activities. BPTQ inhibits the proliferation of HL-60 cells by arresting cells at S and G2/M phase with an IC50 value of 12 µmol/L. BPTQ also activates the mitochondria-mediated Apoptosis pathway by a decrease in mitochondrial membrane potential, increase in the Bax:Bcl-2 ratio and activation of caspases.
-
AG-28262
0 ImagesCat. No.: HY-116721CAS No.: 638216-89-4AG-28262 is a VEGFR inhibitor. AG-28262 has anti-angiogenesis activity.
-
(E)-FeCP-oxindole
0 ImagesCat. No.: HY-108444ACAS No.: 884338-18-5(Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC50 value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC50 less than 1 μM.
-
AhR modulator-1
0 ImagesCat. No.: HY-135671CAS No.: 118174-38-2AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus.
-
AGW-11
0 ImagesCat. No.: HY-175820AGW-11 is a potent dual inhibitor of EGFR (IC50 = 556 nM) and VEGFR2 (IC50 = 289.7 nM). AGW-11 induces apoptosis and suppresses phosphorylation of EGFR, VEGFR2, and ERK1/2 in HUVECs. AGW-11 effectively inhibits cancer cell growth, reduces HUVEC proliferation, tube formation, and invasion, thereby blocking angiogenesis. AGW-11 significantly suppresses tumor growth and decreases lung metastasis in a 4T1 xenograft mouse model. AGW-11 can be used for the study of breast cancer.
-
YF-452
0 ImagesCat. No.: HY-120200CAS No.: 1951466-83-3YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research.
-
YS07
0 ImagesCat. No.: HY-162509YS07 is a potent VEGFR-2 inhibitor. Molecular dynamics simulation study revealed sustained interactions of YS07 with key amino acids of VEGFR-2 at a run time of 100 ns. YS07 can be used for anticancer research.
